课题基金 / 基金详情

BG9719 & FUROSEMIDE FOR CONGESTIVE HEART FAILURE & RENAL INSUFFICIENCY

BG9719 & FUROSEMIDE FOR CONGESTIVE HEART FAILURE & RENAL INSUFFICIENCY
BG9719
批准号：
6265131
负责人：
D CRAIG BRATER
金额：
$0.04万
依托单位：
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6265131
关键词：
adenosine alpha antiadrenergic agent chronic renal failure clinical research clinical trial phase I congestive heart failure diuretics drug screening /evaluation furosemide heart disorder chemotherapy human subject human therapy evaluation kidney disorder chemotherapy

项目摘要

项目成果

D CRAIG BRATER的其他基金

相关文献

中文摘要
翻译
BG9719是一种有效的高选择性腺苷a1受体拮抗剂，通过减少近端和远端肾元中腺苷a1介导的钠重吸收而引起利尿。此外，BF9719对腺苷a1介导的传入小动脉收缩的拮抗作用阻断了小管-肾小球反馈回路。因此，BG9719干扰肾脏对远端肾元高盐负荷释放的腺苷下调肾小球滤过的能力，这进一步有助于其利尿作用。
英文摘要
BG9719 is a potent and highly selective adenosine A1-receptor antagonist that causes diuresis by reducing adenosine A1-mediated sodium reabsorption in both the proximal and distal nephron. In addition, antagonism of adenosine A1-mediated constriction of the afferent arteriole by BF9719 interrupts the tubuloglomerular feedback loop. Consequently, BG9719 interferes with the kidney's ability to down regulate glomerular filtration in response to adenosine released by a high salt load in the distal nephron, which further contributes to its diuretic effects.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Diuretics on Response to Torsemide in Patients with Congestive Heart Failure
General Clinical Research Ctr:Pharmacogenetics Core Supp
MULTICENTER DOUBLE BLIND PLACEBO CONTROLLED STUDY TO EVALUATE AND COMPARE
MULTICENTER DOUBLE BLIND PLACEBO CONTROLLED STUDY TO EVALUATE AND COMPARE